Chronic myeloide leukemia: Natural history and classification;Leucemia mielóide crônica: História natural e classificação

Revista Brasileira de Hematologia e Hemoterapia

Volumn 30, Issue SUPPL. 1, 2008, Pages 3-7

  Bortolheiro, Teresa Cristina ^a   Chiattone, Carlos Sergio ^a,b  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Classification; CML; Disease progression; Prognostic factors; Staging

Indexed keywords

EID: 55949123952     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842008000500003     Document Type: Review

References (23)

1. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005;80(3):390-402.
2. Bortolheiro TC. Avaliação de fatores prognósticos e das respostas hematológica, citogenética e molecular em pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe. Tese de mestrado, Faculdade de Ciências Médicas da Santa Casa de São Paulo, 2007
3. Lorand-Metze I, Pagnano KBB, Vieira VA, Delamain MT, Rossini MS, Metze K. Fatores que influem na resposta citogenética com o uso do imatinibe em pacientes com leucemia mielóide crônica. Rev. bras. hematol. hemoter. 2005; 27(Supl.2): abst 365.
4. Funke VAM, Medeiros CR, Lima DH, Setúbal DC, Bitencourt MA, Bonfim CM, et al. Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: study of 98 cases. Rev. bras. hematol. hemoter. 2005;27(3):159-65.
5. Campos MG, Arantes AM, Oliveira JSR, Chauffaille MLLF. Considerações sobre idade e perfil de apresentação em leucemia mielóide crônica. Rev. bras. hematol. hemoter. 2006; 28(Supl.2): Abstr.452.
6. Bandeira DMA, Melo MC, Freire CJ, Chee HC. Análise do perfil epidemiológico dos pacientes com leucemia mielóide crônica do hospital universitário Prof. Alberto Antunes no período de 1996 a 2005. Rev. bras. hematol. hemoter. 2006;28(Supl.2): Abstr.442.
7. Hellwig TMC, Nachtigal G, Zago A, Faggion J, Bebber FE, Almeida R, et al. Avaliações de variáveis sociodemograficas e clínicas dos pacientes com diagnóstico de leucemia mielóide crônica atendidos no Serviço de Oncohematologia do Hospital Escola UFPEL. Rev. bras. hematol. hemoter. 2006;28(Supl.2): Abstr.449.
8. Gordon MY, Marley SB, Apperley JF, Marin D, Kaeda J, Szydlo R, et al. Clinical heterogeneity in chronic myeloid leukemia refleting biological diversity in normal persons. Br J Haematol. 2003;424-9.
9. Beutler E. Discrepancies between genotype and phenotype in hematolgy: an important frontier. Blood. 2001;98:2597-602.
10. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40(1):79-86.
11. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005;353(5):498-507.
12. Cortes JE, Talpaz M, O'Brien S, Faderi S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era. An evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306-15.
13. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104(7):1979-88.
14. Melo JV, Hochhaus A, Yan XH, Goldman JM. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol. 1996;92(3):684-6.
15. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101(1):97-100.
16. Alvarez RH, Kantarjian HM, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin hematol. 2007;44 (1Suppl 1):S4-S14.
17. Goldman JM, Melo JVM. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 349;15:1451-64.
18. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma. 2006;47(3):381-96.
19. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-56.
20. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
21. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer. 2005;103(10):2099-108 (a).
22. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005;46(7):993-7 (b).
23. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004 (c).